The CBD market is growing but why does that new reality bother bosses over at Big Pharma so much?
The human body is replete with cannabinoid receptors which are located throughout the organs. Various isolated cannabis compounds are known to trigger those receptors, offering a wide variety of solutions for those suffering with chronic pain, nausea and migraine headaches, as well as a host of other ailments.
It’s no big secret that Pharma bosses don’t like the prospect of something medicinal that grows naturally. After all, that reality would hit them hard right where it hurts. And that’s why they are more keen to keep patients addicted to their patented chemicals, and not steer them towards CBD.
To that end, some at Big Pharma are pushing for legislation, at least in North America, which would actually make CBD oil and other products illegal. Just a few months ago, lobbyists for GW Pharmaceuticals and its U.S. subsidiary, Greenwich BioSciences, fought for an amendment to the bill that would have limited CBD rescheduling to products approved by the Food and Drug Administration (FDA). To make CBD legally obtainable.
Since no pharmaceutical company has a CBD type drug anywhere close to market, and the wide range of CBD products already available in medical cannabis states lack FDA approval, CBD users are left with a problem, and not one easily solved.
Then there’s the other not small issue of full spectrum cannabis extracts Vs. pure CBD – two very different things. While the former is not at all suitable for children, say with epilepsy, the latter is, and that grey area is a minefield, not only for legislators, but more importantly for the people who need CBD or medical cannabis the most – patients.
The fact that Pharma strength CBD products could become a reality means that the big CBD war will soon itself be surpassed by another war – a money war – as the difference in costs between natural CBD oil and a pill are massive. And when it comes to money wars, especially at that level, it’s never good news for patients.
[Image Credit: Pixabay]
